Welcome to our dedicated page for TELEFLEX SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teleflex Incorporated filings document the regulatory record for a medical technology issuer with global product categories in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Periodic and current reports disclose operating results, GAAP and non-GAAP measures, revenue adjustments, foreign-currency effects, acquisition and integration items, divestiture-related costs, reserves and other factors affecting reported performance.
Teleflex 8-K filings also cover material events, executive and board transitions, compensation arrangements, shareholder communications, material agreements, capital-structure disclosures and clinical or regulatory matters when reported. Proxy materials disclose director elections, board committee matters, executive compensation, equity awards, pay-versus-performance information and shareholder voting items.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC filed a Schedule 13G disclosing beneficial ownership in Teleflex Inc. (TFX). They reported 2,366,131 shares of common stock, representing 5.35% of the class as of 09/30/2025.
The filing lists shared voting power over 2,366,131 shares and shared dispositive power over the same amount, with no sole voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Teleflex (TFX) reported a sharp swing to loss on non-cash charges. For the quarter ended September 28, 2025, net revenues were $913,021, up from $764,375 a year ago, reflecting contributions from the newly acquired Vascular Intervention business. However, the company posted a net loss of $(408,892), driven primarily by a $403,925 goodwill impairment in Interventional Urology and a $100,000 impairment tied to Titan SGS.
Operating trends were mixed: gross profit rose to $451,642, but higher SG&A and R&D, plus restructuring and separation costs, pressured results. Year‑to‑date, revenue reached $2,394,579 while net loss was $(191,310). Teleflex closed the BIOTRONIK Vascular Intervention acquisition for €704.3 million ($825.2 million) and financed it with a $700 million delayed draw term loan and additional revolver borrowings. Total borrowings increased to $2,681,250, and cash from operations was $188,971 year‑to‑date as investing cash outflows reflected the acquisition.
The company is advancing plans to separate NewCo, with $32,144 in year‑to‑date separation costs. Shares outstanding were 44,194,408 as of November 4, 2025.
Teleflex Incorporated (TFX) furnished an earnings press release and slide presentation announcing results for the quarter ended September 28, 2025. The materials were provided under Items 2.02 and 7.01.
The press release includes non-GAAP metrics: adjusted revenue growth, adjusted constant currency revenue growth, and adjusted diluted EPS. Adjusted revenue excludes an increase in reserves tied to Italy’s medical device “payback” measure following a recent court ruling. Adjusted diluted EPS excludes, as applicable, restructuring and rationalization, impairment, acquisition/integration/divestiture items, separation costs for the RemainCo/NewCo plan, pension termination charges, EU MDR registration costs, intangible amortization, ERP implementation and related IT transition costs, tax adjustments, and dilutive shares impact.
The information is furnished, not filed, and is not incorporated by reference unless expressly stated. Exhibits include the earnings release (99.1) and conference call slides (99.2).
Teleflex (TFX) received an amended Schedule 13G/A from BlackRock, Inc. reporting beneficial ownership of 5,158,480 shares of common stock, representing 11.7% of the class as of 09/30/2025. BlackRock reports sole voting power over 5,053,017 shares and sole dispositive power over 5,158,480 shares, with no shared voting or dispositive power.
BlackRock certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF holds an interest in Teleflex common stock that is more than five percent of outstanding shares.
Janus Henderson Group plc is disclosed as a beneficial owner of Teleflex Incorporated common stock, reporting an aggregate 4,149,271 shares representing 9.4% of the class. The filing indicates no sole voting or dispositive power and instead reports shared voting and dispositive power over the reported shares.
The Janus Henderson Enterprise Fund is shown holding 2,885,870 shares (6.5%) with shared voting and dispositive power. The filing includes a certification that the shares were acquired and are held in the ordinary course of business and not to influence control. The document is signed by Kristin Mariani and contains a power of attorney authorizing certain officers to execute ownership filings.
Teleflex Inc. (TFX) Form 4: Director Stuart A. Randle executed an open-market purchase of 1,000 common shares on 08/05/2025 at a weighted-average price of $115.86 (trade range $115.53–$116.06). The transaction is coded “P,” confirming it was a direct–purchase rather than an option exercise or gift. After the buy, Randle’s direct ownership rises to 7,547 shares, an increase of roughly 15% in his personal stake.
No derivative securities were involved and there were no dispositions. Insider buying—especially by an independent director—can serve as a modest positive signal of management confidence and alignment with shareholder interests, though the dollar value (~$116k) is not large relative to Teleflex’s market capitalization.